Breaking News
Novavax
About Novavax
We are a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases.
We have more than a decade of experience contending with some of the world’s most devastating diseases, including COVID-19, seasonal influenza, RSV, Ebola, MERS, and SARS. Hard-won lessons and significant advances illustrate that our proven technology has tremendous potential to make a substantial contribution to public health worldwide.
Our vaccine candidates are genetically engineered using three-dimensional nanostructures of recombinant proteins critical to disease pathogenesis.
We are also developing proprietary immune-stimulating saponin-based adjuvants at Novavax AB, our wholly owned Swedish subsidiary. Matrix-M™ has been shown to enhance immune responses and has been well tolerated in multiple clinical trials.
U.S. Government and Novavax Extend Partnership, Securing Up to 1.5 Million Additional Doses of Novavax' COVID-19 Vaccine
February 13 2023
Novavax, a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, […]
Novavax Names John C. Jacobs as New President & Chief Executive Officer
January 10 2023
Novavax, a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, […]
Novavax Makes One Million Doses of Nuvaxovid™ Available for Use in the United Kingdom
September 28 2022
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for […]
Novavax Announces Expanded Agreement with SK bioscience to Manufacture COVID-19 Vaccine Containing Omicron Variant and Manufacture the Novavax COVID-19 Vaccine in Prefilled Syringes
July 20 2022
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for […]
U.S. FDA Grants Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted for Individuals Aged 18 and Over
July 15 2022
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for […]
U.S. Government Secures 3.2 Million Doses of Novavax COVID-19 Vaccine
July 12 2022
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious […]
Novavax COVID-19 Vaccine Nuvaxovid™ Provisionally Registered in Australia as a Booster in Individuals Aged 18 and Over
June 14 2022
Novavax, Inc. (NASDAQ: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious […]
Novavax Initiates Phase 3 Trial of its COVID-19 Omicron Strain Vaccine as a Booster
June 1 2022
Novavax today announced the initiation of its Phase 3 strain change trial to determine if […]
Novavax Announces Participation in Oxford University Com-COV3 Booster Trial of COVID-19 Vaccines in Adolescents Aged 12 Through
May 26 2022
Novavax is participating in a stage of the COVID-19 Vaccine Schedule Combinations (Com-COV) program initiated by the […]
Novavax Announces Extended Durability of Protection Against Infection and Disease in United Kingdom COVID-19 Vaccine Phase 3 Clinical Trial
March 1 2022
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious […]
Novavax Files for Authorization of its COVID-19 Vaccine in the United Kingdom
October 27 2021
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious […]
Results from Novavax NanoFlu Influenza Vaccine Phase 3 Clinical Trial Published in The Lancet Infectious Diseases
September 24 2021
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious […]
Novavax and European Commission Finalize Advance Purchase Agreement for up to 200 Million Doses of COVID-19 Vaccine
August 5 2021
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today […]
Novavax COVID-19 Vaccine Demonstrates 90% Overall Efficacy and 100% Protection Against Moderate and Severe Disease in PREVENT-19 Phase 3 Trial
June 14 2021
Novavax, Inc. (Nasdaq: NVAX), today announced that NVX-CoV2373, its recombinant nanoparticle protein-based COVID-19 vaccine, demonstrated 100% […]
Novavax Announces Positive Preclinical Data for Combination Influenza and COVID-19 Vaccine Candidate (NanoFlu/NVX-CoV2373)
May 10 2021
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced […]
Novavax and Gavi Execute Advance Purchase Agreement for COVID-19 Vaccine for COVAX Facility
May 6 2021
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced […]
NEJM Publishes Efficacy of Novavax Vaccine Against B.1.351 Variant
May 6 2021
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced […]
Novavax Initiates Pediatric Expansion for Phase 3 Clinical Trial of COVID-19 Vaccine
May 5 2021
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced […]
Malaria Vaccine Phase 2b Clinical Trial Results Published in Preprints with The Lancet
April 23 2021
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced […]
Novavax to Participate in Comparing Mixed COVID-19 Vaccine Combinations
April 15 2021
Novavax, Inc., a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced its […]
Novavax to Participate in Fireside Chat at Goldman Sachs Virtual Conference
April 8 2021
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced […]
GSK to support manufacture of Novavax' COVID-19 vaccine
March 30 2021
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, GSK and the […]